In LARS-OE cells, BC-LI-0186 treatment markedly reduced S6K phosphorylation and significantly but not completely inhibited LAT1 protein expression, which remained notably higher than in wild-type cells (Figure 5C). Here, LARS1 is linked to breast cancer.